{
  "outcomes_metadata": {
    "timestamp": "2025-09-19T15:13:47.931771",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 54,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "Overall survival (OS; time from randomization to death from any cause) [AT, ES, EN, NL, FR, SE, DK, PT, PO, DE, IT, DK (guideline), NL (guideline), BE, PO (guideline), SE (guideline), EU]",
        "All-cause mortality (death due to any cause) [AT, DE]",
        "Reduction in HCC-related mortality [EU]",
        "Long-term survival [IT, DK (guideline)]",
        "5-year survival [DK (guideline)]",
        "Prolongation of survival [NL (guideline)]"
      ],
      "response_measures": [
        "Objective response rate (ORR; percentage of patients with partial or complete response according to RECIST 1.1 and/or mRECIST criteria) [ES, FR, DK, PT, PO, DE, AT (guideline), SE (guideline), BE, PO (guideline), NL (guideline)]",
        "Tumor response rate [AT, DE]",
        "Complete response (CR; as defined by mRECIST or RECIST) [DK, PO, DE, AT (guideline)]",
        "Partial response (PR; as defined by mRECIST or RECIST) [DK, PO, DE, AT (guideline), BE]",
        "Stable disease (SD) [DK, PO]",
        "Disease control rate (DCR; includes CR, PR, and SD) [AT, ES, FR, DK, PO]",
        "Clinical benefit rate (CBR) [FR, DK]",
        "Therapeutic efficacy [ES (guideline)]",
        "Tumor reduction [AT, DE]",
        "Tumor control (as reviewed after two treatment cycles) [AT (guideline), DE (guideline)]",
        "Local control/local tumor control [AT, DE, NL (guideline), DK (guideline)]",
        "Success rate (downstaging/bridging) [NL (guideline)]",
        "Secondary resectability [AT (guideline), DE (guideline)]",
        "Assessment of response to treatment (RECIST/mRECIST for systemic/locoregional therapy) [PO (guideline)]",
        "Response rates (RECIST criteria) [ES (guideline), FR (guideline), SE (guideline), BE, PO (guideline), IT (guideline)]"
      ],
      "progression_measures": [
        "Progression-free survival (PFS; time from randomization to tumor progression or death, defined by RECIST 1.1) [ES, EN, FR, SE, DK, PT, PO, DE, NL (guideline), AT (guideline)]",
        "Time to progression (TTP; time from randomization to disease/tumor progression) [AT, ES, FR, DK, PT, PO, DE, AT (guideline), PO (guideline), NL (guideline)]",
        "Time to symptomatic progression (TTSP) [AT, DE]",
        "Time to patient-reported impairment of quality of life [ES]",
        "Time to radiological disease progression [EN]",
        "Time to symptom progression [NL, AT (guideline)]",
        "Time to deterioration [AT (guideline), DE (guideline)]",
        "Time to response [DK]",
        "Time in health states (progression-free, progressive illness, death) in partitioned survival model [SE]",
        "Bridging therapy and reduction of progression (locoregional methods) [PO (guideline)]",
        "Early detection of local recurrence or de novo tumor [NL (guideline)]",
        "Disease recurrence/recurrence detection [AT, DE, ES (guideline), BE]",
        "Delay of recurrence [BE]",
        "Tumor recurrence [FR (guideline)]"
      ]
    },
    "safety": {
      "adverse_events": [
        "Adverse events (including grade 3/4 or III/IV adverse reactions such as hand-foot skin reaction, diarrhea, hypertension, skin rash or desquamation, hepatotoxicity, hepatic encephalopathy, hepatic insufficiency, hypothyroidism, renal events, arterial thromboembolic events, haemorrhagic events, proteinuria, diabetes mellitus, loss of appetite, weight loss, gastrointestinal disorders, bleeding, infections, infusion reactions, hyperthyroidism, and others) [AT, ES, EN, NL, FR, SE, DK, PT, PO, DE, IT, DK (guideline), NL (guideline), BE, PO (guideline), SE (guideline), EU]",
        "Adverse events (graded according to CTCAE v5.0 or National Cancer Institute criteria) [FR (guideline), SE (guideline), PT]",
        "Treatment-emergent adverse events (TEAEs) [DK, PO]",
        "Adverse reactions (including serious and grade 3/4) [NL]",
        "Adverse events leading to discontinuation, dose reduction, or suspension [ES, FR, DK, PT, PO, DE]",
        "Drug withdrawal due to adverse events [PT]",
        "Dropout rate for toxicity [PT]",
        "Treatment-related mortality/deaths [FR, PT]",
        "Serious adverse events/adverse reactions [ES, EN, NL, FR, DK, PT, PO, DE, IT, DK (guideline), BE, PO (guideline), SE (guideline), EU]",
        "Complications (including intraoperative, long-term, and specific complications such as bleeding, tumour seeding, liver failure, pain, fever, leukaemia, gallbladder abscess, postoperative softening) [AT, DE, NL (guideline), DK (guideline), BE, EU]",
        "Serious complications [BE, DK (guideline)]",
        "Safety and tolerability in patients with hepatic dysfunction [NL]",
        "Safety assessments (vital signs, laboratory haematological and biochemical testing, urinalysis, electrocardiography) [PT]",
        "Patient safety [SE (guideline)]",
        "Contraindication due to portal vein thrombosis [BE]",
        "Side-effects of biopsy [EU]",
        "Undesirable effects on the development of hepatocellular carcinoma [PO (guideline)]"
      ],
      "serious_events": [
        "Serious adverse events/adverse reactions (as above) [ES, EN, NL, FR, DK, PT, PO, DE, IT, DK (guideline), BE, PO (guideline), SE (guideline), EU]",
        "Grade 5 adverse events [ES]",
        "Long-term treatment-related complications [ES (guideline)]"
      ],
      "discontinuations": [
        "Discontinuation or dose modification due to adverse events [ES, FR, DK, PT, PO, DE]",
        "Discontinuation of treatment due to adverse events [EN, FR, DK, PT, PO, DE]",
        "Dose reduction due to adverse events [PT, PO]",
        "Drug withdrawal due to adverse events [PT]",
        "Dropout rate for toxicity [PT]"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "Health-related quality of life (HRQoL; measured by EORTC QLQ-C30, EORTC QLQ-HCC18, EQ-5D, EQ-5D VAS, FACT-G, FACT-Hep, and other validated instruments) [AT, ES, EN, FR, SE, DK, PT, PO, DE, NL (guideline), DK (guideline), SE (guideline), IT (guideline)]",
        "Quality of life (subjective global assessment, global health status, function scales) [AT, DE, NL (guideline), DK (guideline), BE, IT (guideline)]",
        "Enhancement of quality of life [NL (guideline)]",
        "Time to clinically meaningful deterioration in HRQoL domains (role functioning, pain, diarrhoea from EORTC QLQ-C30; nutrition, body image from EORTC QLQ-HCC18) [DK]",
        "Time to patient-reported impairment of quality of life [ES]",
        "Distress (physical and psychological complaints after treatment, reported using a validated screening tool) [NL (guideline)]"
      ],
      "functional_status": [
        "Performance status (ECOG PS, WHO PS 0-1) [SE, SE (guideline), ES (guideline)]",
        "Functional role subscale (EORTC QLQ-C30) [ES]",
        "Fitness sub-scale (EORTC QLQ-C30) [ES]"
      ],
      "symptom_measures": [
        "Symptoms (fatigue, pain, jaundice, fever, abdominal swelling measured by EORTC QLQ-HCC18) [AT, DE]",
        "Symptom assessment (via disease-specific quality of life modules) [SE (guideline)]",
        "Management of symptoms [SE (guideline)]"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "Cost-effectiveness (incremental cost-effectiveness ratio, ICER; cost per QALY; cost-benefit analysis; cost/benefit ratio of surveillance) [EN, NL, FR, SE, DK, PO, IT (guideline)]",
        "Budget impact [NL]",
        "Total treatment costs [NL]",
        "Cost-effectiveness analysis [NL]",
        "Resource use estimates [SE, DK]",
        "Need for use of medical resources [ES]"
      ],
      "utilities": [
        "Quality-adjusted life years (QALYs) [EN, SE, DK, PO]",
        "Quality of life weights and health state utility values [SE]"
      ],
      "resource_utilization": [
        "Length of hospital stay [AT, DE]",
        "Days of missed work [AT, DE]",
        "Resource use estimates [SE, DK]",
        "Number needed to treat (NNT) [PO]",
        "Number needed to harm (NNH) [PO]"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "Therapeutic value [CZ]",
        "Interchangeability with medicines included in the insured package [CZ]",
        "Success rate (downstaging/bridging) [NL (guideline)]",
        "Early detection of HCC [EU, SE (guideline)]",
        "Detection of early HCC (using ultrasound and serum AFP measurement) [EU]",
        "False-positive results (with addition of serum AFP to ultrasound) [EU, IT (guideline)]",
        "Diagnostic accuracy [DK (guideline)]",
        "Accurate diagnosis (using multiphasic CT and MRI following LI-RADS v2018) [EU]",
        "Pathological assessment of diagnosis, prognosis, and tumour subtypes (using immunohistochemistry panels) [EU]",
        "Molecular classification of HCC subtypes [EU]",
        "Prognosis (BCLC staging system, Child-Pugh and MELD scores, tumour stage, severity of underlying liver disease, patient performance status) [ES (guideline), IT (guideline), DK (guideline)]",
        "Post-treatment follow-up to assess therapeutic efficacy and detect recurrences [ES (guideline)]",
        "Outcomes after liver transplantation (Milan criteria, UCSF-expanded criteria) [IT (guideline)]",
        "Down-staging prior to liver transplantation (intention-to-treat analysis) [IT (guideline)]",
        "Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection [IT (guideline)]",
        "Safety and efficacy of radiotherapy [IT (guideline)]",
        "Tolerance of treatment in patients with Child-Pugh B liver cirrhosis [IT (guideline)]",
        "Quality of treatment [SE (guideline)]",
        "Comfort [SE (guideline)]",
        "Structured follow-up [SE (guideline)]",
        "Comparison of outcomes between treatment modalities (e.g., resection vs. locoregional methods) [PO (guideline)]",
        "Completeness of ablation (assessed by multiphase CT with contrast) [PO (guideline)]",
        "Follow-up imaging after ablation (MRI or multiphasic CT at defined intervals) [PO (guideline)]",
        "Resectability status [SE (guideline)]"
      ],
      "biomarkers": [
        "Liver function (Child-Pugh classification, liver function assessment, hepatic dysfunction) [AT, DE, FR, SE (guideline), ES (guideline), NL, DK (guideline)]",
        "Tumour spread assessment (size, number, vascular invasion, extrahepatic spread, TNM system) [SE]",
        "Alpha-fetoprotein (AFP) at time of detection of focal liver lesion [IT (guideline), EU]",
        "Immunohistochemistry markers [EU]",
        "Plasma pharmacokinetics parameters [DK, PT]",
        "Pharmacokinetic/pharmacodynamic relationship between exposure and efficacy/safety [DK]",
        "Biochemical testing [PT]",
        "Laboratory haematological testing [PT]",
        "Urinalysis [PT]",
        "Electrocardiography [PT]"
      ]
    }
  }
}